Organization (Academic)
Oregon Health & Science University
ClinicalTrials.gov lists Oregon Health & Science University as lead sponsor of 936 trials, counting the companies grouped under it. Oregon Health & Science University itself has 77 active development programs and 167 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 51 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 57 in 2026 and about 52 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 4 trials are registered to start in 2027 or later.
This page covers Oregon Health & Science University and 1 company grouped under it: 936 lead-sponsored trials (693 its own, 243 in the grouped companies) and 4 legal-entity registrations (3 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| OHSU Knight Cancer Institute | 243 | 1 |
Disease areas (595)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Prostatic Neoplasms | 56 |
| Pain | 53 |
| Diabetes Mellitus | 51 |
| Parkinson Disease | 47 |
| Breast Neoplasms | 39 |
Showing 5 of 595 disease areas.
Trials by start year as sponsor or collaborator (34)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 51 |
| 2025 | 46 |
| 2024 | 56 |
| 2023 | 59 |
| 2022 | 49 |
| 2021 | 52 |
| 2020 | 43 |
| 2019 | 63 |
| 2018 | 73 |
| 2017 | 48 |
Showing 10 of 34 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 71 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 472 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (77)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Treatment As Usual | Substance-Related Disorders | Phase 3 | 3 |
| Treatment As Usual | Opioid-Related Disorders | Phase 3 | 3 |
| Amiodarone Hydrochloride Injection | Heart Arrest | Phase 3 | 1 |
| Blood components transfusion | Brain Injuries, Traumatic | Phase 3 | 1 |
| Whole blood transfusion | Brain Injuries | Phase 3 | 1 |
Showing 5 of 77 active programs.
Approved assets (167)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Treatment As Usual | 6 |
| DONEPEZIL | 4 |
| Lidocaine | 3 |
| Tamoxifen | 3 |
| SEVOFLURANE | 2 |
Showing 5 of 167 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 34% hit target (n=265) | 35% on time (n=233) |
Journals published in (853)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| International forum of allergy & rhinology | 45 |
| The New England journal of medicine | 41 |
| The Laryngoscope | 34 |
| Obstetrics and gynecology | 26 |
| The Journal of clinical endocrinology and metabolism | 23 |
Showing 5 of 853 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 511 | 97 | 2025-12-30 |
Financing and grant events (2,927)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-06-23 | NIH grant | 798,240 | Reporter |
| 2026-04-08 | NIH grant | 153,410 | Reporter |
| 2025-09-30 | NIH grant | 33,674 | Reporter |
| 2025-09-30 | NIH grant | 178,235 | Reporter |
| 2025-09-25 | NIH grant | 396,355 | Reporter |
Showing 5 of 2,927 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 24 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Oregon Health and Science University | Portland, US | FDA |
Organization relationships (330)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 160 |
| University of California System | Co sponsors trial with | 26 |
| Roche (Switzerland) | Co sponsors trial with | 14 |
| Harris Health System | Co sponsors trial with | 11 |
| Columbia University | Co sponsors trial with | 10 |
Showing 5 of 330 relationships.
Latest dated events (4,662)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-04-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 4,662 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| OREGON HEALTH AND SCIENCE UNIVERSITY | Certificate of waiver | Terminated |
Biomarker capability evidence (1,420)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AATF | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ABRAXAS1 | Trial collaborator | Named in trial inclusion criteria |
| ACADVL | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 1,420 evidence rows.
Biomarkers this organization publishes on (1,862)
Shown in this order: most publications first.
Showing 5 of 1,862 biomarkers.
On Scientist.com
Oregon Health & Science University is listed as a research supplier in the Scientist.com network.
Service areas
Oregon Health & Science University (OHSU) offers microscopy, flow cytometry, histopathology, genotyping, proteomics, DNA/RNA synthesis, DNA sequencing, and transgenic model services.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, and workforce and board diversity, as filed.
Work with Oregon Health & Science University - Knight Cancer Institute on Scientist.com
For prices, more details, or to contact Oregon Health & Science University - Knight Cancer Institute, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.